Voacamine is a novel inhibitor of EGFR exerting oncogenic activity against colorectal cancer through the mitochondrial pathway
| Autor: | Yao Chen, Jirui Yang, Yi Zuo, Chaozheng Zhang, Yiru Pu, Qing Ren, Xiao Li, Yunqian Huang, Hui Huang, Huan Yang, Ouyang You, Xila Xia, Aiping Lu, Sanjun Shi, Yun Deng, Jun Lu |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Pharmacology
Biological Products TOR Serine-Threonine Kinases NF-kappa B Apoptosis Mitochondria ErbB Receptors Mice Phosphatidylinositol 3-Kinases Adenosine Triphosphate Proto-Oncogene Proteins c-bcl-2 Cell Line Tumor Ibogaine Animals Colorectal Neoplasms Reactive Oxygen Species Proto-Oncogene Proteins c-akt Cell Proliferation Signal Transduction bcl-2-Associated X Protein |
| Zdroj: | Pharmacological Research. 184:106415 |
| ISSN: | 1043-6618 |
| DOI: | 10.1016/j.phrs.2022.106415 |
| Popis: | Colorectal cancer (CRC), among the most aggressive and prevailing neoplasms, is primarily treated with chemotherapy. Voacamine (VOA), a novel bisindole natural product, possesses a variety of conspicuous pharmacological activities. Within the current research, we evaluated in vitro and in vivo the anticancer efficacy of VOA against CRC and its potential mechanisms. Our results illustrated that VOA concentrationdependently suppressed the proliferation and migration of CT26 and HCT116 cells as correspondingly indicated by IC |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect